علاقة فيريتين المصل بالمؤشرات الكبدية والكلويّة والغدّية في الثلاسيميا الكبرى من النوع بيتا: دراسة مقطعية

References

1. Agarvas, A., Kopf, S., Lopes, T., Atkins, J., Thalmann, P., Fernández-Real, J. M., Nawroth, P. P., & Muckenthaler, M. U. (2025). Iron biomarkers predict peripheral artery disease in females. Atherosclerosis, 402, 119111. https://doi.org/10.1016/j.atherosclerosis.2025.119111

2. Aliberti, L., Gagliardi, I., Gamberini, M. R., Ziggiotto, A., Verrienti, M., Carnevale, A., Bondanelli, M., Zatelli, M. C., & Ambrosio, M. R. (2022). Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria. British Journal of Haematology, 198(1), 121–128. https://doi.org/10.1111/bjh.18182

3. Cao, A., & Galanello, R. (2023). Beta-thalassemia. Genetics in Medicine. https://doi.org/10.1038/s41436-023-02345-7

4. Caocci, G., Orofino, M., Vacca, A., Piroddi, A., Piras, E., Addari, M., Carìa, R., Pilia, M., Origa, R., Moi, P., & La Nasa, G. (2017). Long‐term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. American Journal of Hematology, 92(12), 1303–1310. https://doi.org/10.1002/ajh.24898

5. Casale, M., Citarella, S., Filosa, A., De Michele, E., Palmieri, F., Ragozzino, A., Amendola, G., Pugliese, U., Tartaglione, I., Della Rocca, F., Cinque, P., Nobili, B., and Perrotta, S. (2014). Endocrine function and bone disease during long‐term chelation therapy with deferasirox in patients with β‐thalassemia major. American Journal of Hematology, 89(12), 1157–1163. https://doi.org/10.1002/ajh.23844

6. Casale, M., Musallam, K. M., Filosa, A., Di Tucci, A. A., Amenata, M., Pinto, V., Gamberini, M. R., Spasiano, A., Origa, R., Maggio, A., Forni, G. L., & Perrotta, S. (2021). Serum ferritin and iron relationship in patients with β‐thalassemia major: Real‐world data from the Luspatercept clinical program. American Journal of Hematology, 96(11), E408–E411. https://doi.org/10.1002/ajh.26310

7. Christodoulou, R., Vamvouras, G., Sarquis, M., Petrou, V., Papageorgiou, P., Rivera, L., Gonzalez, C., Rivera, G., Papageorgiou, S., & Vassiliou, E. (2025). From microbleeds to iron: AI prediction of cerebrospinal fluid erythrocyte load in Alzheimer’s disease. Journal of Clinical Medicine, 14(20), 7360. https://doi.org/10.3390/jcm14207360

8. Chyad, L. A., Al-Budairi, A. S., & Shakir, W. H. (2026). Exploring immunological, microbial, and other contributing factors in the deterioration of health among patients with uncontrolled diabetes: A community-based study to identify causes and solutions. Journal of Basic Science, 21(38), 641–675. https://doi.org/10.31185/bsj.Vol21.Iss38.933

9. Cunningham, M. J., Macklin, E. A., Neufeld, E. J., & Cohen, A. R. (2004). Complications of beta-thalassemia major in North America. Blood, 104(1), 34–39. https://doi.org/10.1182/blood-2003-09-3167

10. De Sanctis, V., Soliman, A. T., Candini, G., Campisi, S., Pepe, A., Kattamis, A., ... & El-Hakim, I. Z. (2013). Insulin resistance and glucose intolerance in β-thalassemia major: A multicenter study from the International Network on Endocrine Complications in Thalassemia (I-NET). Diabetes & Metabolism, 39(5), 441–448. https://doi.org/10.1016/j.diabet.2013.06.001

11. Eren, F., Yozgat, A. K., Fırat Oğuz, E., Neşelioğlu, S., Firat, R., Gürlek Gökçebay, D., Yaralı, H., Özbek, N., & Erel, Ö. (2023). A new perspective for potential organ damage due to iron-mediated oxidation in thalassemia major patients. Journal of Clinical Medicine, 12(5), 1234. https://doi.org/10.3390/jcm12051234

12. Evangelidis, P., Venou, T., Fani, B., Vlachaki, E., and Gavriilaki, E. (2023). Endocrinopathies in hemoglobinopathies: What is the role of iron? International Journal of Molecular Sciences, 24(21), 15345. https://doi.org/10.3390/ijms242115345

13. Farmaki, K., Tzoumari, I., Pappa, C., Chouliaras, G., and Berdoukas, V. (2010). Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. British Journal of Haematology, 148(3), 466–475. https://doi.org/10.1111/j.1365-2141.2009.08098.x

14. Forni, G., Gianesin, B., Musallam, K. M., Longo, F., Rosso, R., Lisi, R., Gamberini, M. R., Pinto, V. M., Graziadei, G., Vitucci, A., Bonetti, F., Musto, P., Piga, A., Cappellini, M. D., & Borgna Pignatti, C. (2023). Overall and complication free survival in a large cohort of patients with β thalassemia major followed over 50 years. American Journal of Hematology, 98(1), 54–64. https://doi.org/10.1002/ajh.26798

15. Galle, P. R., Decaens, T., Kudo, M., Qin, S., Fonseca, L. G., Sangro, B., & Yau, T. (2024). Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: First results from CheckMate 9DW. Journal of Clinical Oncology, 42(17), LBA4008. https://doi.org/10.1200/jco.2024.42.17_suppl.lba4008

16. Habeb, A. M., Al-Alwan, I., Al-Agha, A. E., De Sanctis, V., Soliman, A. T., & the International Endocrine Group. (2025). International consensus on the diagnosis and management of endocrine complications of β and α thalassemia in children and adolescents. Hormone Research in Paediatrics. https://doi.org/10.1159/000540123

17. Hassan, T. H., El-Sayed, H. I., El-Gazar, H. E., Meabed, M. H., El-Kholy, M. S., & Helwa, M. A. (2020). Endocrine complications and bone mineral density in children and adolescents with beta-thalassemia major: A single-center study. Egyptian Journal of Haematology, 45(1), 47–53. https://doi.org/10.4103/ejh.ejh_43_19